ArticleVirology journal2022
Stability of enveloped and nonenveloped viruses in hydrolyzed gelatin liquid formulation.
Article in Virology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Stabilization of spray-dried monoclonal antibody formulations with polymeric excipients.Journal of pharmaceutical sciences · 2026Article
- Pilot Assessment of RNA Stabilization Methods for Influenza A Virus in Swine Oral Fluids.Pathogens (Basel, Switzerland) · 2026Article
- Polymers as Stabilizing Excipients for Spray-Dried Protein Formulations.Pharmaceutical research · 2026Article
- Inactivation of Viruses by Charged Cinnamaldehyde Nanoemulsions.Foods (Basel, Switzerland) · 2025Article
- Retention of locally injected human iPS cell-derived cardiomyocytes into the myocardium using hydrolyzed gelatin.Scientific reports · 2025Article
- Chemical and Heat Treatment for Viral Inactivation in Porcine-Derived Gelatin.BMC biotechnology · 2024Article
- Analytical Performance of a Novel Nanopore Sequencing for SARS-CoV-2 Genomic Surveillance.Journal of medical virology · 2024Article
- Backflow reduction in local injection therapy with gelatin formulations.Drug delivery · 2024Article
- Development of Long-Term Stability of Enveloped rVSV Viral Vector Expressing SARS-CoV-2 Antigen Using a DOE-Guided Approach.Vaccines · 2024Article
- Stabilization of an Infectious Enveloped Virus by Spray-Drying and Lyophilization.Journal of pharmaceutical sciences · 2024Article
- Investigation of the effectiveness of gelatin hydrolysate in human iPS-RPE cell suspension transplantation.Regenerative therapy · 2024Article
- Study of Oncolytic Virus Preservation and Formulation.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe thermal stability of viruses in gelatin liquid formulations for medical research and application is poorly understood and this study aimed to examine the thermal stability of 4 enveloped and nonenveloped DNA and RNA viruses in hydrolyzed gelatin liquid formulations.
methodsBovine herpesvirus (BHV) was used as a model virus to examine the molecular weight (MW), concentration and gelatin type and to optimize virus stability in liquid formulations at 25 °C and 4 °C. Using the model virus liquid formulation, the stability of multiple enveloped and nonenveloped RNA and DNA viruses, including parainfluenza virus, reovirus (RV), BHV, and adenovirus (AdV), was monitored over up to a 30-week storage period.
resultsThe BHV model virus was considered stable after 3 weeks in hydrolyzed gelatin (MW: 4000) with a 0.8 LRV (log10 reduction value) at 25 °C or a 0.2 LRV at 4 °C, compared to the stabilities observed in higher MW gelatin (60,000 and 160,000) with an LRV above 1. Based on the gelatin type, BHV in alkaline-treated hydrolyzed gelatin samples were unexpectantly more stable than in acid-treated hydrolyzed gelatin sample. All four viruses exhibited stability at 4 °C for at least 8 weeks, BHV or AdV remained stable for over 30 weeks of storage, and at 25 °C, AdV and RV remained stable for 8 weeks.
conclusionThe results demonstrated that 5% of 4000 MW hydrolyzed gelatin formulation can act as a relevant stabilizer for the thermal stability of viruses in medical research and application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.